| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A portion of amino acids 120-152 from the human protein was used as the immunogen for the MBD2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target |
Overview
MBD2 Antibody / Methyl-CpG-binding domain protein 2 is an antibody targeting MBD2, raised in Rabbit for protein detection and localization studies where these specifications are required.
Key elements and design rationale
- Target: MBD2.
- Antibody identity: Polyclonal (rabbit origin); Rabbit Ig.
- Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
- Format: Purified.
- Species reactivity: Human, Mouse.
- Listed applications: WB (refer to on-page specifications for application-specific guidance).
Biological background
MBD2 is part of a family of proteins that possess a methyl-CpG-binding domain, allowing them to recognize and bind to DNA that has been modified by the addition of methyl groups. This binding has important implications for gene expression, as methylation can either activate or repress gene transcription. One of the most intriguing aspects of MBD2 is its ability to recruit other proteins to the methylated DNA, influencing the chromatin structure and ultimately determining whether a particular gene is switched on or off. This dynamic interplay between MBD2 and other regulatory proteins highlights the complexity of epigenetic regulation. Research into MBD2 has uncovered its involvement in a wide range of biological processes, from embryonic development to cancer progression. Dysregulation of MBD2 has been linked to aberrant gene expression patterns seen in various diseases, making it a potential target for therapeutic interventions.
Research relevance and current trends
- Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
- Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
- Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.
Common research applications
- Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.
Notes for experimental interpretation
- Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
- Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
- Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
- Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
